Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a ...

Merck KGaA has announced that it will be acquiring SpringWorks Therapeutics for approximately $3.9bn. The definitive ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to SpringWorks ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

FRANKFURT, April 28 (Bernama-dpa) - German health care and science group Merck has sealed a deal to bolster its cancer ...

Huawei preparing to test latest AI chip to challenge Nvidia (NVDA): report. Merck KGaA to buy Springworks for $3.9 billion.

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

Revvity reported first-quarter results above Wall Street estimates and maintained its full-year profit forecast on Monday, ...

Strategic Acquisition to Expand Oncology Portfolio Deal Overview:German healthcare and materials giant Merck KGaA (NSE: PROR) ...

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion, as the ...